Navigation Links
U.S. Preventive Medicine and deCODE Genetics Sign Letter of Intent to Expand Personalized Medicine Platform
Date:4/3/2008

DALLAS and REYKJAVIK, Iceland, April 3, 2008 /PRNewswire/ -- U.S. Preventive Medicine(R), (http://www.USPreventiveMedicine.com) the leader in prevention, and deCODE Genetics, the global leader in gene discovery, today announced they have signed a letter of intent to add genetic testing to expand both companies' personalized medicine services in the U.S. and internationally.

"The signing of the letter of intent with deCODE is significant because we will be the first entity in the U.S. and internationally to offer a full continuum of geographically dispersed, comprehensive solutions for personalized medicine including preventive care, wellness and disease management," said Christopher Fey, Chairman and CEO of U.S. Preventive Medicine. "We are very excited because our consumer, employer and physician customers will now be able to take advantage of a wide range of innovative personalized medicine services, including an opt-in genetic testing program for clients of our Centers for Preventive Medicine and members of The Prevention Plan. Our goal is to make the most advanced prevention strategies -- including more precise risk stratification -- available to informed consumers who want to use the best medicine has to offer to enjoy more good years."

Fey said U.S. Preventive Medicine's expansion into personalized medicine is the next step in the company's plan to provide practical solutions at every point in the healthcare continuum both nationally and internationally.

"The relationship with U.S. Preventive Medicine will offer us another platform to provide our genetic testing and personal genetics services through an innovative business model encompassing Centers for Preventive Medicine, as well as its new Prevention Plan health benefits," says Kari Stefansson, M.D., CEO of deCODE. "This partnership gives deCODE access to an even wider distribution channel of consumers, employers and providers to share knowledge, experiences, new technologies and services, while providing the best possible preventive health programs."

According to U.S. Preventive Medicine National Policy Advisor and former Secretary of the U.S. Department of Health & Human Services, Gov. Tommy Thompson, "The addition of deCODE's DNA profiling services as a option for the individuals the company assists is a natural evolution in the direction of the demand for personalized medicine. This is a very important step for U.S. Preventive Medicine in their role as the leader of this crucial area of health care."

About U.S. Preventive Medicine:

U.S. Preventive Medicine(R), a privately owned company, is building the first personalized medicine business in the United States and internationally focused on prevention. They offer employers, government agencies and consumers proprietary products that include The Prevention Plan(TM), a groundbreaking personalized wellness program delivered online to individuals; The Prevention Plan CM(TM), field-based chronic disease management programs customized for employers and government agencies to reduce healthcare costs; and The Centers for Preventive Medicine(R), which offer high-tech diagnostic screenings delivered to consumers in partnership with hospitals, health systems and other providers. For more information, please visit http://www.USPreventiveMedicine.com.

About deCODE

deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery -- our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. deCODE is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in personal genome analysis, DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development. deCODE is delivering on the promise of the new genetics. Visit us on the web at http://www.decode.com; on our diagnostics website at http://www.decodediagnostics.com; and, for our pioneering personal genome analysis service, at http://www.decodeme.com.


'/>"/>
SOURCE U.S. Preventive Medicine, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. U.S. Preventive Medicine National Policy Advisor Gov. Tommy Thompson to Propose Prevention is the Solution at UBS Global Health Services Conference
2. Protherics UK Ltd. Chooses TrackWise for Corrective Action and Preventive Action (CAPA) Management
3. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
4. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
5. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
6. NeoStems Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus
7. Partnership With SearchMedica.com to Enhance Web Searches on ModernMedicine.com
8. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
9. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
10. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
11. Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") (en.tusholdings.com) ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):